Amyl Therapeutics

company

About

Amyl Therapeutics is a preclinical stage biotechnology company.

Details

Last Funding Type
Series A
Last Funding Money Raised
€8.60M
Industries
Biotechnology,Health Care,Life Science,Medical
Founded date
Nov 1, 2020
Number Of Employee
1 - 10
Operating Status
Active

Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€18.30M
Amyl Therapeutics has raised a total of €18.30M in funding over 2 rounds. Their latest funding was raised on Jun 3, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 3, 2021 Series A €8.60M 7 Meusinvest (Noshaq) Detail
Jun 3, 2021 Grant €9.70M 1 Directorate General operational for Economy, Employment and Research Detail

Employee Profiles

Number of Employee Profiles
8
Amyl Therapeutics has 8 current employee profiles, including Executive Florent Gros
Executive
Executive
Board member
Board member
Board member